Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity

Human Gene Therapy

Volumn 9, Issue 17, 1998, Pages 2481-2492

  Puisieux, Isabelle ^a   Odin, Laurence ^a   Poujol, Dominique ^a   Moingeon, Philippe ^b   Tartaglia, James ^c   Cox, William ^c   Favrot, Marie ^a  

^a CENTRE LÉON BÉRARD   (France)

^b Pasteur Merieux Connaught Grp   (France)

^c Virogenetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE TRANSFER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; POXVIRUS; T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; AVIPOXVIRUS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CERCOPITHECUS AETHIOPS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; LUCIFERASES; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; VERO CELLS;

ANIMALIA; CANARYPOX VIRUS; MURINAE; MUS MUSCULUS; POXVIRIDAE;

EID: 0032553697     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349850019328     Document Type: Article

References (30)

1. ALLIONE, A., CONSALVO, M., NANNI, P., LOLLINI, P., CAVALLO, F., GIOVARELLI, M., FORNI, M., GULINO, A., COLOMBO, M., DELLABORA, P., HOCK, H., BLANKENSTEIN, T., ROSENTHAL, F., GANSBACHER, B., BOSCO, M., MUSSO, T., GUSELLA, L., and FORNI, G. (1994). Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin IL2, IL4, IL6, IL7, tumor necrosis factor α, granulocyte-macrophage colony-stimulating factor and γ-interferon gene or admixed with conventional adjuvants. Cancer Res. 54, 6022-6026.
2. ARMSTRONG, C., BOTELLA, R., GALLOWAY, T., MURRAY, N., KRAMP, J., SUNG SONG, I., and ANSEL, J. (1996). Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 56, 2191-2198.
3. BRAMSON, J.L., HITT, M., ADDISON, C.L., MULLER, W.J., GAULDIE, J., and GRAHAM, F.L. (1996). Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7, 1995-2002.
4. BRUNDA, M.J., LUISTRO, L., WARRIER, L., WRIGHT, R., HUBBARD, B., MURPHY, M., WOLF, S., and GATELY, M. (1993). Anti-tumor and anti-metastatic activity of IL12 against murine tumors. J. Exp. Med. 178, 1223-1230.
5. BRUNDA, M.J., LUISTRO, L., HENDRZAK, J.A., FOUNTOULAKIS, M., GAROTTA, G., and GATELY, M.K. (1995). Role of IFNγ in mediating the antitumor efficacy of IL12. J. Immunother. 17, 71-77.
6. CARUSO, M., PHAM-NGUYEN, K., KWONG, Y.-L., XU, B., KOSAI, K.-I., FINEGOLD, M., WOO, S., and CHEN, S.-H. (1996). Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. U.S.A. 93, 11302-11306.
7. CAVALLO, F., SIGNORELLI, P., GIOVARELLI, M., MUSIANI, P., MODESTI, A., BRUNDA, M., COLOMBO, M., and FORNI, G. (1997). Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89, 1049-1058.
8. CAYEUX, S., BECK, C., AICHER, A., DÖRKEN, B., and BLANKENSTEIN, T. (1995). Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol. 25, 2325-2331.
9. COLOMBO, M., VAGLIANI, M., SPREAFICO, F., PARENZA, M., CHIODONI, C., MELANI, C., and STOPPACCIARO, A. (1996). Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56, 2531-2554.
10. COUGHLIN, C.M., WYSOCKA, M., KURZAWA, H., LEE, W., TRINCHERI, G., and ECK, S. (1995). B7.1 and Interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55, 4980-4987.
11. DRANOFF, G., JAFFEE, E., LAZENBY, A., GOLUMBEK, P., LEVITSKY, H., BROSE, K., JACKSON, V., HAMADA, H., PARDOL, D., and MULLIGAN, R. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539-3543.
12. FRIES, L.F., TARTAGLIA, J., TAYLOR, J., KAUFFMAN, E.K., MEIGNIER, B., PAOLETTI, E., and PLOTKIN, S. (1996). Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system. Vaccine 14, 428-434.
13. GATELY, M.K., and CHIZZONITE, R. (1998). Measurement of human and mouse interleukin 12. In Current Protocols in Immunology. J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, and W. Strober, eds. (Greene Publishing and Wiley-Interscience, New York) pp. 6.16.1-6.16.9.
14. HUANG, A.Y.C., GOLUMBEK, P., AHMADZADEH, M., JAFFEE, E., PARDOLL, D., and LEVITSKY, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965.
15. LOLLINI, P.-L., BOSCO, M.C., CAVALLO, F., DE GIOVANNI, C., GIOVARELLI, M., LANDUZZI, L., MUSIANI, P., MODESTI, A., NICOLETTI, G., PALMIERI, G., SANTONI, A., YOUNG, H.A., FORNI, G., and NANNI, P. (1993). Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer 55, 320-329.
16. MARSHALL, E. (1995). Cancer trial of interleukin-12 halted. Science 268, 1555.
17. MARTINOTTI, A., STOPPACCIARO, A., VAGLIANI, M., MELANI, C., SPREAFICO, F., WYSOCKA, M., PARMIANI, G., TRINCHIERI, G., and COLOMBO, M. (1995). CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25, 137-146.
18. MOSS, B. (1996). Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A. 93, 11341-11348.
19. NANNI, P., DE GIOVANNI, C., LOLLINI, P.L., NICOLETTI, G., and PRODI, G. (1983). TS/A: A new metastasizing cell line originated from a Balb-c spontaneous mammary adenocarcinoma. Clin Exp. Metastasis 1, 373-376.
20. NASTALA, C., EDINGTON, H., MCKINNEY, T., TAHARA, H., NALESNIK, M., BRUNDA, M., GATELY, M., WOLF, S., SCHREIBER, R., STORKUS, W., and LOTZE, M. (1994). Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153, 1697-1700.
21. NOGUCHI, Y., RICHARDS, E., CHEN, Y.-T., and OLD, L. (1995). Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. U.S.A. 92, 2219-2223.
22. PAOLETTI, E. (1996). Applications of pox virus vectors to vaccination: An update. Proc. Natl. Acad. Sci. U.S.A. 93, 11349-11353.
23. PERKUS, M.E., LIMBACH, K., and PAOLETTI, E. (1989). Cloning and expression of foreign genes in vaccinia virus using host range selection system. J. Virol. 63, 3829-3836.
24. ROTH, J., and CRISTIANO, R. (1997). Gene therapy for cancer: What have we done and where are we going? J. Natl. Cancer Inst. 89, 21-39.
25. ROTH, J., DITTMER, D., REA, D., TARTAGLIA, J., PAOLETTI, E., and LEVINE, A. (1996). p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc. Natl. Acad. Sci. U.S.A. 93, 4781-4786.
26. TAHARA, H., ZITVOGEL, L., STORKUS, W., ZEH H., III, MCKINNEY, T., SCHREIBER, R., GUBLER, U., ROBBINS, P., and LOTZE, M. (1995). Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154, 6466-6474.
27. TARTAGLIA, J., PERKUS, M.E., TAYLOR, J., NORTON, E.K., AUDONNEY, J.C., COX, W.I., DAVIS, S.W., VAN DER HOEVEN, J., MEIGNIER, B., RIVIERE, M., LANGUET, B., and PAOLETTI, E. (1992). NYVAC: A highly attenuated strain of vaccinia virus. Virology 188, 217-232.
28. WAKIMOTO, H., ABE, J., TSUNODA, R., AOYAGI, M., HIRAKAWA, K., and HAMADA, H. (1996). Intensified antitumor immunity by cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 56, 1828-1833.
29. ZITVOGEL, L., TAHARA, H., ROBBINS, P., STORKUS, W., CLARKE, M., NALESNIK, M., and LOTZE, M. (1995). Cancer immunotherapy of established tumors with IL12. J. Immunol. 155, 1393-1403.
30. ZITVOGEL, L., ROBBINS, P., STORKUS, W., CLARKE, M., MAEURER, M., CAMPBELL, R., DAVIS, G., TAHARA, H., SCHREIBER, R., and LOTZE, M. (1996). Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26, 1335-1341.